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Summary
Background Intradermal MVA85A, a candidate vaccine against tuberculosis, induces high amounts of Ag85A-speciﬁ c 
CD4 T cells in adults who have already received the BCG vaccine, but aerosol delivery of this vaccine might oﬀ er 
immunological and logistical advantages. We did a phase 1 double-blind trial to compare the safety and immunogenicity 
of aerosol-administered and intradermally administered MVA85A
Methods In this phase 1, double-blind, proof-of-concept trial, 24 eligible BCG-vaccinated healthy UK adults were 
randomly allocated (1:1) by sequentially numbered, sealed, opaque envelopes into two groups: aerosol MVA85A and 
intradermal saline placebo or intradermal MVA85A and aerosol saline placebo. Participants, the bronchoscopist, and 
immunologists were masked to treatment assignment. The primary outcome was safety, assessed by the frequency 
and severity of vaccine-related local and systemic adverse events. The secondary outcome was immunogenicity 
assessed with laboratory markers of cell-mediated immunity in blood and bronchoalveolar lavage samples. Safety and 
immunogenicity were assessed for 24 weeks after vaccination. Immunogenicity to both insert Ag85A and vector 
modiﬁ ed vaccinia virus Ankara (MVA) was assessed by ex-vivo interferon-γ ELISpot and serum ELISAs. Since all 
participants were randomised and vaccinated according to protocol, our analyses were per protocol. This trial is 
registered with ClinicalTrials.gov, number NCT01497769.
Findings Both administration routes were well tolerated and immunogenic. Respiratory adverse events were rare and 
mild. Intradermal MVA85A was associated with expected mild local injection-site reactions. Systemic adverse events 
did not diﬀ er signiﬁ cantly between the two groups. Three participants in each group had no vaccine-related systemic 
adverse events; fatigue (11/24 [46%]) and headache (10/24 [42%]) were the most frequently reported symptoms. 
Ag85A-speciﬁ c systemic responses were similar across groups. Ag85A-speciﬁ c CD4 T cells were detected in 
bronchoalveolar lavage cells from both groups and responses were higher in the aerosol group than in the intradermal 
group. MVA-speciﬁ c cellular responses were detected in both groups, whereas serum antibodies to MVA were only 
detectable after intradermal administration of the vaccine.
Interpretation Further clinical trials assessing the aerosol route of vaccine delivery are merited for tuberculosis and 
other respiratory pathogens.
Funding The Wellcome Trust and Oxford Radcliﬀ e Hospitals Biomedical Research Centre.
Copyright © Satti et al. Open Access article distributed under the terms of CC BY. 
Introduction
Tuberculosis is caused by inhalation of Mycobacterium 
tuberculosis and remains a major global public health 
problem, causing 1·3 million deaths worldwide in 2012. 1 
The only licensed vaccine, intradermal BCG, is eﬀ ective 
in preventing disseminated tuberculosis, but confers a 
highly variable degree of protection against pulmonary 
tuberculosis, especially in adults.2,3
One tuberculosis vaccine development strategy is to 
boost BCG with a subunit vaccine expressing one or more 
M tuberculosis antigens. An advanced candidate vaccine is 
modiﬁ ed vaccinia virus Ankara (MVA) expressing the 
highly conserved M tuberculosis antigen 85A (MVA85A). 
Given systemically, MVA85A induces potent 
Ag85A-speciﬁ c CD4 T-cell responses in BCG-vaccinated 
adults.4
Inhalation of infectious droplets containing M tuberculosis 
bacilli is the most common natural route of M tuberculosis 
infection. Delivery of a tuberculosis vaccine directly to the 
respiratory mucosa might enhance local protective 
immune responses at the primary site of infection. 
Systemically administered BCG protects against systemic 
disease in childhood.2,5 Airway vaccination might be needed 
to optimise protection against pulmonary disease. Studies 
in mice show that the location of antigen-speciﬁ c cells in 
the airway is important for protection against M tuberculosis 
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challenge.6 Recombinant MVA vectors delivered to mucosa 
induced high levels of mucosal immunity in animal 
models.7 Aerosol administration of MVA in non-human 
primates was safe and induced potent and long-lasting 
antigen-speciﬁ c immunity.8 Aerosol delivery of a 
tuberculosis vaccine could oﬀ er logistic beneﬁ ts over 
intradermal administration. This approach is feasible with 
aerosolised measles vaccines.9
In this proof-of-concept, double-blind, randomised 
phase 1 clinical trial, we compare the safety and immuno-
genicity of aerosolised and intradermally administered 
MVA85A in healthy BCG-vaccinated adults in the UK. 
This study is the ﬁ rst clinical evaluation of a candidate 
tuberculosis vaccine delivered by aerosol.
Methods
Study design and participants
Between Nov 10, 2011, and Nov 1, 2012, we enrolled 
24 BCG-vaccinated, healthy adults 18–50 years of age. All 
participants had received their BCG vaccination at least 
6 months before enrolment. Participants were recruited 
from the general population in Oxfordshire, UK, and 
seen and enrolled at the Centre for Clinical Vaccinology 
and Tropical Medicine in Oxford. Enrolled participants 
were in good health and had normal baseline haematology, 
coagulation, and biochemistry; a normal chest radiograph; 
no substantial abnormality of pulmonary function tests; 
and negative serological testing for hepatitis B, hepatitis C, 
and HIV. Latent M tuberculosis infection was excluded by 
a negative ex-vivo interferon-γ ELISpot response to 
M tuberculosis early secreted antigen of 6 kDa (ESAT-6) 
and 10-kDa culture ﬁ ltrate protein (CFP-10) peptides. 
Current smokers, people using nasal or inhaled drugs, 
and those with a history of asthma or other respiratory 
disease were excluded. 38 people were initially screened 
and 14 were excluded (four withdrew consent and ten met 
exclusion criteria). All 24 enrolled participants were 
randomised, vaccinated, underwent bronchoscopy, and 
were followed up for 6 months after vaccination as per 
protocol.
All participants provided written informed consent. 
This phase 1 trial was approved by the Medicines and 
Healthcare Products Regulatory Agency (reference 2010-
022381-27) and Oxfordshire Research Ethics Committee 
A (reference 11/SC/0021). This trial is registered with 
ClinicalTrials.gov, number NCT01497769.
Randomisation and masking
Between Nov 10, 2011, and Nov 1, 2012, we randomly 
allocated eligible participants (1:1) to aerosol MVA85A 
(using the Omron MicroAir U22 ultrasonic mesh nebuliser 
[Omron Healthcare UK Ltd, Milton Keynes, UK]) and 
intradermal saline (group A) or intradermal MVA85A 
(delivered in a volume of 135 μL to the deltoid region of the 
arm by a 29G diameter, 12·7 mm length needle) and 
aerosol saline (group B). Randomisation was done with 
sequentially numbered, opaque, sealed envelopes opened 
by the study clinician at enrolment. Variable blocks (block 
sizes two to eight) in the randomisation sequence ensured 
allocation concealment. For safety reasons, the ﬁ rst 
participant was assigned to the new intervention (group A) 
with a 1 week delay before subsequent enrolments. 
Participants, the bronchoscopist, and immunologists were 
masked to treatment allocation, which was achieved 
through the paired-placebo trial design.
Procedures
The vaccine used was clinical-grade MVA85A (lot number 
010507), which was produced under good manufacturing 
practice conditions by IDT Biologika GmbH (Dessau-
Rosslau, Germany).4 The planned dose of MVA85A was 
1 × 10⁸ plaque-forming units (pfu), as used in previous 
trials. To help nebulisation, we used sterile 0·9% saline to 
make the 135 μL dose up to a volume of 1 mL. In the ﬁ rst 
two participants vaccinated by the aerosol route, this dose 
of MVA85A induced extremely powerful mucosal cellular 
immune responses. These responses at day 7 were higher 
than those previously recorded in non-human primates.8 
In view of the potency of this route of administration, the 
protocol was amended by the principal investigator (and 
approved by the ethics committee and by the Medicines 
and Healthcare Products Regulatory Agency on Dec 22, 
2011, and by the NHS Research and Development team 
on Jan 11, 2012) and the remaining 22 participants were 
vaccinated with MVA85A at a lower dose of 1 × 10⁷ pfu.
We did ﬁ breoptic ﬂ exible bronchoscopies at 7 days after 
vaccination in accordance with British Thoracic Society 
Guidelines.10 After they had provided informed consent, 
participants fasted for 6 h without food and 2 h without 
water, and then received local anaesthesia and light 
sedation with fentanyl and midazolam. The bronchoscope 
was passed through the nose or mouth and local 
anaesthetic was delivered to the vocal cords and trachea. 
The bronchoscope was positioned in the bronchiole of 
the medial segment of the right middle lobe and 50 mL 
sterile 0·9% saline was injected and then aspirated into 
the lung segment. This bronchoalveolar lavage was 
repeated once and the samples placed in Falcon tubes 
(BD Biosciences [Oxford, UK]), which were transferred to 
Jenner Institute Laboratories (Oxford, UK) within 1 h. We 
measured vital signs, including peripheral oxygen 
saturation (SpO2), and monitored participants throughout 
the procedure. Participants were discharged home after 
90 min.
We did the ex-vivo interferon-γ ELISpot assay on fresh 
peripheral blood mononuclear cells separated from 
whole blood as previously described.11 Samples were 
collected at baseline and at 1, 2, 4, 12, and 24 weeks 
after vaccination. Peripheral blood mononuclear cells 
(1 × 10⁵ per well and 3 × 10⁵ per well) were stimulated 
with one pool of 15-mer peptides spanning the length 
of Ag85A, MVA-CD4 and MVA-CD8 T-cell epitopes,12 a 
pool of ESAT-6, and a pool of CFP-10 peptides (Peptide 
Protein Research [Hampshire, UK]), and staphylococcal 
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enterotoxin B from Staphylococcus aureus (Sigma-
Aldrich [Gillingham, UK]).
For the intracellular cytokine staining, bronchoalveolar 
lavage cells were pelleted and stimulated at 1 × 10⁶ with 
2 μg/mL Ag85A peptide pool; negative (unstimulated) 
and positive (staphylococcal enterotoxin B-stimulated) 
controls were included. We used 1 μg/mL of co-
stimulatory αCD28 and αCD49d (BD Biosciences). 
Stimulated and unstimulated cells were incubated at 
37°C in 5% CO2 for 2 h, after which Brefeldin-A (Sigma-
Aldrich) was added before a further overnight incubation.
Whole blood was stimulated as previously described.13 
Brieﬂ y, blood was incubated with 1 μg/mL αCD28, 
1 μg/mL αCD49d (BD Biosciences) and stimulated with 
Ag85A peptide pool, staphylococcal enterotoxin B, or 
unstimulated. Samples were incubated at 37°C in 5% 
CO2 for 6 h, Brefeldin-A was added, and whole blood 
samples were incubated for another 6 h. Red blood cells 
were then lysed and samples were frozen for batched 
intracellular cytokine staining analysis.
We did surface and intracellular cytokine staining as 
previously described.14 Bronchoalveolar lavage cells were 
surface stained for viability (Molecular Probes LIVE/
DEAD ﬁ xable stain, Invitrogen [Paisley, UK]), followed by 
CD4 (clone RPA-T4, Biolegend [London, UK]), CD14 
(clone RMO52), and CD19 (clone J3-119) (Beckman 
Coulter [High Wycombe, UK]). Cells were stained 
intracellularly for CD3 (clone UCHT1), interferon-γ 
(clone 4S.B3, Ebiosciences [Hatﬁ eld, UK]), CD8 (clone 
SK1, BD Biosciences), interleukin-2 (clone N7.48A, 
Beckman Coulter), tumour necrosis factor (TNF)α (clone 
MAB11), and interleukin 17 (clone BL168, Biolegend).
Stimulated whole blood cells were permeabilised and 
stained as detailed previously. Samples were acquired on 
an LSR II ﬂ ow cytometer (BD Biosciences). We analysed 
responses using FlowJo (Tree Star Inc [Ashland, USA]). 
We measured cytokines in live, singlet CD3, CD4, and 
CD8 T cells. The presented results are percentages of 
cytokine-positive cells minus the responses in 
unstimulated cells.
In ELISA, we assessed insert-speciﬁ c and vector-speciﬁ c 
humoral responses (IgG, IgA, and IgM) in serum samples 
collected on days 1, 2, 7, 14, 28, 84, and 168 and 
bronchoalveolar lavage ﬂ uid samples collected on day 7. 
Nunc Immunoplates were coated with recombinant 
Ag85A (Lionex [Braunschweig, Germany]) or wild-type 
MVA and incubated overnight. Plates were then blocked 
and diluted serum or neat bronchoalveolar lavage ﬂ uid 
samples were incubated. We used goat anti-human 
secondary antibody conjugated to alkaline phosphatase 
(Sigma) to detect antibodies, and plates were developed by 
the addition of substrate.
Outcomes
The primary outcome of this trial was safety, which we 
assessed by the frequency and severity of vaccine-
related local and systemic adverse events. Details of 
expected local skin adverse events (pain, erythema, and 
swelling), respiratory adverse events (cough, sore 
throat, wheeze, dyspnoea, sputum production, 
haemoptysis, chest pain, and appearance of bronchial 
mucosa), and systemic adverse events (fever, 
feverishness, fatigue, malaise, headache, myalgia, 
arthralgia, and nausea) were collected from participants 
by the use of a diary card, which the participants self-
completed for 14 days after vaccination. We measured 
routine laboratory bio chemical and haemato logical 
variables at 7 days and 84 days after vaccination.  We 
issued participants with, and trained them in the use 
of, a handheld spirometer (Micro Spirometer, 
CareFusion [San Diego, CA, USA]) for home measure-
ment of forced expiratory volume in 1 s (FEV1) and 
forced vital capacity (FVC), initially twice daily and 
Figure 1: Trial proﬁ le
38 people assessed for eligibility
24 participants enrolled and 
randomised
12 assigned to group A 
(aerosol MVA85A)
12 assigned to group B 
(intradermal MVA85A)
  0 lost to follow-up
  0 withdrew from the study
24 participants completed the study
14 excluded
4 withdrew consent
10 met exclusion criteria
1 respiratory disorder
4 abnormal spirometry
3 psychiatric disorder
1 latent Mycobacterium 
tuberculosis infection
1 pregnancy
Group A: aerosol MVA85A
(n=12)
Group B: intradermal MVA85A
(n=12)
Women 7 (58%) 7 (58%)
Age (years) 21·5 (20–49) 22·0 (20–26)
Time since BCG vaccination (years) 9·0 (1–49) 9·0 (5–23)
Non-smokers 12 (100%) 12 (100%)
BMI (kg/m²) 22·6 (19·8–37·7) 21·3 (18·8–29·4)
Spirometry
% predicted FEV1 99% (80–110) 91% (85–110)
% predicted FVC 100% (83–108) 91% (82–103)
Median baseline % SpO2 98% (97–99) 98% (97–99)
Continent of birth
Europe 11 (92%) 12 (100%)
Africa 1 (8%) 0
Asia 0 0
BMI=body-mass index. FEV1=forced expiratory volume in 1 s. FVC=forced vital capacity. SpO2=peripheral oxygen 
saturation. Data are n (%) or median (range), unless otherwise indicated.
 Table 1: Baseline characteristics
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then daily for 14 days after vaccination. The secondary 
outcome was immunogenicity to both insert (Ag85A) 
and vector (MVA) assessed with laboratory markers of 
cell-mediated immunity in blood and bronchoalveolar 
lavage samples by use of ex-vivo interferon-γ ELISpot, 
intracellular cytokine staining,  and serum ELISAs for 
humoral responses.
Statistical analysis
Safety data are summarised by the frequency and median 
number of adverse events per participant. We used the 
Mann-Whitney U-test to compare adverse events and 
immune responses between groups.
We did an area-under-the-curve (AUC) analysis to 
summate each participant’s response over time. We used 
Mann-Whitney AUC to compare responses in both 
groups. Only results from the low-dose group were 
included in the analysis, because only two participants 
received the high dose and they both received vaccine by 
aerosol so it would be inappropriate to include those in 
the analysis. We judged p values less than 0·05 to be 
statistically signiﬁ cant. Prism Graph Pad Software 
version 5 was used for statistical analysis.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Between Nov 10, 2011, and Nov 1, 2012, 38 healthy adults 
in the UK were screened for inclusion in the trial, and 
14 were excluded (ﬁ gure 1). Therefore, 24 adults were 
judged eligible for inclusion. The baseline characteristics 
of the study participants did not diﬀ er signiﬁ cantly 
between treatment groups (table 1). 
The number of respiratory adverse events did not diﬀ er 
between participants receiving aerosol saline placebo and 
those receiving aerosol MVA85A (median 1·0 events per 
person for saline placebo vs 0·5 for MVA85A; p=0·76). 
Respiratory adverse events were rare and mild in both 
groups (ﬁ gure 2). The most frequent expected (and mild) 
respiratory adverse events after bronchoscopy were 
cough and sore throat (ﬁ gure 2).
Intradermal MVA85A was associated with an expected 
mild local injection-site reaction (injection-site erythema, 
swelling, or other mild local skin reaction; ﬁ gure 3).11 
Intradermal saline was non-reactogenic.
Systemic adverse events did not diﬀ er signiﬁ cantly 
between the groups (table 2). Three participants in each 
group had no vaccine-related systemic adverse events. In 
the other participants, mild fatigue (11/24 [46%]) and 
mild-to-moderate headache (10/24 [42%]) were the most 
common symptoms (mostly mild, but two participants 
had moderate headache in group A). One person in each 
group reported feverishness after vaccination. A 
documented mild fever (37·7°C) occurred in one 
intradermally vaccinated participant, on the evening after 
vaccination.
The ﬁ rst participant vaccinated by the aerosol route, 
who received the higher dose of MVA85A (1 × 10⁸ pfu), 
reported a mild vesicular skin rash on the right side of 
her face that appeared 11 days after vaccination. This rash 
was diagnosed as shingles (varicella zoster virus) in the 
right C2 dermatome by her family doctor and conﬁ rmed 
by viral PCR. The patient was given oral aciclovir and 
simple analgesics and recovered completely in 10 days. 
Shingles was not detected in any other participant.
No clinically signiﬁ cant abnormalities of laboratory 
tests at 7 days or 84 days after vaccination were recorded. 
No serious adverse events occurred in the trial.
SpO2 was normal and stable (mean SpO2 >97%) 
throughout the trial in all but one participant (in the 
Figure 2: Respiratory and systemic adverse events after bronchoscopy and bronchoalveolar lavage
(A) Frequency of mild respiratory adverse events in each group during the ﬁ rst 7 days after vaccination. All events were 
mild and did not diﬀ er signiﬁ cantly between the groups. (B) Frequency of respiratory adverse events on each of the 
14 days after vaccination for both groups combined. Day 7 is the day of bronchoscopy. As expected, bronchoscopy and 
bronchoalveolar lavage was associated with non-sustained respiratory adverse events, especially cough and sore 
throat, in some participants.
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intradermal MVA85A group) who developed hyper-
salivation, profuse coughing, and transient desaturation 
to SpO2 88%, before bronchoscopic cannulation of the 
vocal cords. The participant was given oxygen and 
recovered rapidly in about 60 s; bronchoscopy then 
proceeded uneventfully. This event was judged to be 
unrelated to vaccination.
Treatment had no clinically signiﬁ cant eﬀ ect on FEV1 
in either group, from immediately after vaccination (at 
10 min and 60 min) and throughout follow-up (ﬁ gure 4). 
Four people were judged to have mildly erythematous 
mucosa at bronchoscopy, two of whom had received 
aerosol MVA85A and two intradermal MVA85A (and 
aerosol saline). The bronchial mucosa of the other 
20 participants was normal. Bronchoalveolar lavage was 
obtained successfully from all participants with a median 
return volume of 46 mL from a 100 mL lavage (equating 
to a median yield of 5·4 × 10⁶ lymphocytes).
For the secondary outcome of immunogenicity, both 
aerosol and intradermal MVA85A (1 × 10⁷ pfu) induced 
signiﬁ cant systemic Ag85A-speciﬁ c responses, as 
measured by ex-vivo interferon-γ ELISpot assay (spot-
forming cells per 1 × 10⁶ peripheral blood mononuclear 
cells; appendix). AUC analysis did not diﬀ er between the 
groups (p=0·9212). Both routes of vaccination with 
1 × 10⁷ pfu MVA85A also induced MVA CD4 and CD8 
T-cell responses (appendix). The MVA CD4 T-cell 
response was higher in the aerosol group than in the 
intradermal group (p=0·0358), but the size of the MVA 
CD8 T-cell response did not diﬀ er signiﬁ cantly between 
the two groups (p=0·5319).
2·5 million to 9 million cells were recovered from 
bronchoalveolar lavage, which was independent of the 
vaccine administration route (data not shown).
Both intradermal and aerosol MVA85A (1 × 10⁷ pfu) 
induced CD4 T cell interferon γ, TNFα, interleukin 2, 
and interleukin 17 in the bronchoalveolar lavage. The 
aerosol administration route induced higher numbers 
of some Ag85A-speciﬁ c CD4 cell cytokines (appendix).
In the whole blood, interferon-γ-producing CD4 T cells 
increased signiﬁ cantly after vaccination (appendix), and 
remained signiﬁ cantly increased compared with baseline 
for up to 4 weeks in the aerosol group and up to 24 weeks 
in the intradermal group. The numbers of CD4 T cells 
making TNFα, interleukin 2, and interleukin 17 increased 
after vaccination in both groups (appendix). Both routes of 
vaccination induced CD4 T cells that produced several 
cytokines (appendix).
Ag85A-speciﬁ c interferon-γ-producing CD8 T cells were 
detectable in the bronchoalveolar lavage in both groups 
(appendix). No other cytokines were detected in the 
Ag85A-speciﬁ c CD8 T-cell population (data not shown).
Aerosol vaccination did not induce increased non-
speciﬁ c lung cytokine responses compared with intra-
dermal vaccination (data not shown).
Anti-MVA IgG titres were signiﬁ cantly higher in the low-
dose intradermal group than in the low-dose aerosol group 
at days 14, 28, 84, and 168 after vaccination (appendix; 
p<0·0001). Anti-MVA IgA titres were signiﬁ cantly higher 
in the low-dose intradermal group than in the aerosol 
group from day 14 after vaccination (appendix; p=0·0003). 
The amounts of anti-MVA IgM did not diﬀ er signiﬁ cantly 
between the two groups (appendix).
No signiﬁ cant eﬀ ect on Ag85A IgG, IgA, and IgM 
responses was detected in either group (appendix). No 
Figure 3: Local and systemic adverse events associated with aerosol and 
intradermal MVA85A vaccination
Box and whisker plots showing the diameter (mm) of injection-site erythema 
(A) and swelling (B) in participants in each group for 7 days after vaccination. 
The dashed line on each graph represents the threshold between mild and 
moderate grading. Local reactions were negligible in the aerosol group 
compared with the intradermal group. (C) Frequency and severity of 
injection-site pain in each of the ﬁ rst 7 days after vaccination with either 
aerosol or intradermal MVA85A. Participants given aerosol MVA85A received 
a concurrent intradermal injection of saline, which was non-reactogenic.
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antibodies were detectable in bronchoalveolar lavage ﬂ uid 
(data not shown).
In the two participants who received the high dose 
(1 × 10⁸ pfu) of aerosol MVA85A, blood and bronchoalveolar 
lavage ex-vivo interferon-γ ELISpot responses exceeded the 
limit of detection using 3 × 10⁵ cells per well; therefore, data 
from 1 × 10⁵ cells per well are presented (table 3). One 
participant had high anti-MVA CD4 and CD8 T-cell 
interferon-γ responses at 1 week after vaccination. High 
numbers of cells making Ag85A-speciﬁ c cytokines were 
detected in the bronchoalveolar lavage from both 
participants. Most interferon-γ-producing CD4 T cells also 
produced TNFα and interleukin 17. Interferon γ from CD8 
T cells was also detected in these samples. Frequencies of 
whole blood CD4 T cells producing interferon γ, TNFα, 
interleukin 2, and interleukin 17 were also high in these 
two participants (table 3). Anti-MVA antibody responses 
were similar to those detected in the low-dose aerosol 
group (table 3).
Discussion
Our results show that aerosol vaccination with MVA85A 
is feasible, safe, and can induce mycobacteria-speciﬁ c 
mucosal and systemic cellular immune responses.
Respiratory adverse events after aerosol delivery were 
rare and did not diﬀ er between the two groups, which 
suggests that the adverse events are caused by the 
nebulised delivery technique rather than by MVA85A 
itself. Bronchoscopic airway examination, FEV1, FVC, 
and SpO2 were within normal limits, providing further 
reassuring evidence for the absence of harm to the 
airways. Systemic reactogenicity of MVA85A adminis-
tered by both routes was mild, which is consistent with 
previous trials.
Although an isolated case of shingles occurred in one 
participant 11 days after aerosol administration of MVA85A, 
no previous vaccine-related cases of shingles have been 
reported in more than 2500 recipients of intradermal 
MVA85A (H McShane, unpublished). Shingles is quite 
common in the general population and has been reported 
to occur before 45 years of age in 8·6% of healthy men and 
10·5% of healthy women.15 In a recent US phase 1 trial of a 
novel live recombinant BCG tuberculosis candidate 
vaccine, two of eight participants developed shingles within 
2–3 months of vaccination.16
The aerosol route of immunisation induced potent 
antigen-speciﬁ c T-cell responses in the bronchoalveolar 
lavage and in the systemic circulation. Compared with 
the intradermal vaccination route, the aerosol route 
induced equally strong systemic responses and signiﬁ -
cantly stronger bronchoalveolar lavage responses. The 
cytokines measured—interferon γ, TNFα, interleukin 2, 
and interleukin 17—are important for the control of 
mycobacterial infection.17–20 The intradermal route also 
induced lung CD4 T-cell responses, although these were 
of a smaller size than those induced by the aerosol route. 
In non-human primates, systemic administration of 
MVA85A induced mucosal responses at a lower level than 
recorded in people;8 however, in mice, systemic delivery 
of a recombinant adenoviral vector does not induce 
mucosal responses.21
CD8 T cells are thought important in defence against 
tuberculosis.22,23 We detected antigen-speciﬁ c CD8 T cells 
in bronchoalveolar lavage in both groups. Mucosal CD8 
T cells are inducible by mucosal vaccination with 
adenovirus-vectored Ag85A and are crucial for protection 
against tuberculosis.21
Although we noted a rise in the numbers of lung cells 
making cytokines in the aerosol group, this increase was 
not accompanied by an increase in the total number of 
lymphocytes recruited to the lungs. This ﬁ nding 
contradicts a previous study reporting a threefold increase 
in total bronchoalveolar lavage cells in puriﬁ ed protein 
derivative-reactive people challenged mucosally with 
puriﬁ ed protein derivative.24 This discrepancy might be 
attributable to the nature of the antigen used, which was 
Ag85A in our study. An increase in inﬂ ux of lymphocytes 
to the lungs was mediated by interferon-γ-inducible and 
interleukin-17-inducible CXCR3;20,25 in the present study 
we did not assess the expression of this chemokine.
Pre-existing immunity to the vector might reduce 
insert-induced immunity.26 Here, we show that systemic 
Group A: aerosol MVA85A
(n=12)
Group B: intradermal MVA85A
(n=12)
Fever 0 1 (8%)
Feverish 1 (8%) 1 (8%)
Arthralgia 0 1 (8%)
Myalgia 0 2 (17%)
Malaise 2 (17%) 2 (17%)
Fatigue 5 (42%) 6 (50%)
Headache 5 (42%) 5 (42%)
Nausea and vomiting 1 (8%) 0
Most expected systemic adverse events were mild (with the exception of two cases of moderate headache in the 
aerosol group) and did not diﬀ er clinically between the groups. For simplicity, we report the adverse events of the 
12 participants in each group collectively, even though the ﬁ rst two participants (both in group A) received a tenfold 
higher dose of vaccine than did the other 22 participants.
Table 2: Frequency and severity of expected systemic adverse events in each group in the ﬁ rst 7 days 
after vaccination
Figure 4: Mean percentage change in FEV1 from baseline at each timepoint 
for both treatment groups
FEV1=forced expiratory volume in 1 s.
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administration of the vaccine induced systemic antivector 
humoral immune responses—a phenomenon that is 
overcome by aerosol vaccination. In this study, we could 
not detect antivector or anti-insert antibodies in 
bronchoalveolar ﬂ uid from any participants, possibly 
because the ﬂ uid is highly diluted. A vaccination route 
that does not induce immunity to the vector, which could 
interfere with insert-induced responses, is an attractive 
approach for vaccines that need repeat administration.
The two participants who received high-dose MVA85A 
had higher systemic and mucosal Ag85A responses than 
did those who received the lower dose. Because the two 
participants who received the high dose were randomly 
allocated to the aerosol group, whether or not a similarly 
high intradermal dose would lead to an increase in cellular 
mucosal responses is unclear. One of the two participants 
who had the high dose had a strong anti-MVA interferon-γ 
response (both CD4 and CD8 T cells).
MVA85A has been given intradermally in all previous 
trials in human beings, including the recent eﬃ  cacy trial 
in tuberculosis-exposed BCG-vaccinated infants, in which 
immunogenicity was modest and no signiﬁ cant enhanced 
eﬃ  cacy was recorded.27 Direct delivery of the vaccine to 
the lungs might improve immunogenicity and eﬃ  cacy. 
Nebulisation of BCG provided superior protection against 
M tuberculosis challenge compared with that conferred by 
intradermal vaccination in non-human primates.28 The 
immunological basis for this enhanced protection is not 
clear. Preferential circulation of memory lymphocytes 
back to the tissues in which they ﬁ rst encountered antigen 
might underlie the limited eﬃ  cacy of the intradermally 
High-dose (1 × 10⁸ pfu) 
participant TB026-301
High-dose (1 × 10⁸ pfu) 
participant TB026-303
Median (IQR) response for 
low-dose (1 × 10⁷ pfu) aerosol 
MVA85A
Median (IQR) response for 
low-dose (1 × 10⁷ pfu) intradermal 
MVA85A
Ex-vivo PBMC interferon-γ ELISpot responses (spot-forming cells/1 × 106 PBMCs)
PBMC 85A interferon γ
(1 × 10⁵ cells/well)
4985 5000 1965 (490–3659) 1010 (681–1490)
PBMC MVA CD4 interferon γ
(3 × 10⁵ cells/well)
212 10 16 (5–111) 10 (1–21)
PBMC MVA CD8 interferon γ
(3 × 10⁵ cells/well)
817 30 2·5 (1–46·5) 13·5 (1·3–24·3)
Intracellular cytokines in BAL and WB (% of T cells producing cytokines)
BAL CD4 interferon γ 17·3% 21·2% 2·0% (1·1–5·8) 0·7% (0·3–1·2)
BAL CD4 TNFα 10·5% 19·3% 2·3% (0·9–5·2) 0·6% (0·1–1·9)
BAL CD4 interleukin 17 3·2% 6·8% 0·6% (0·3–1·4) 0·2%  (0·1–0·3)
BAL CD8 interferon γ 0·7% 2·5% 0·1% (0·1–0·6) 0·1% (0·03–0·3)
WB CD4 interferon γ 1·4% 0·7% 0·3% (0·1–0·6) 0·1% (0·1–0·2)
WB CD4 TNFα 1·3 % 0·6% 0·2% (0·1–0·4) 0·1% (0·1–0·2)
WB CD4 interleukin 2 1·1% 0·6% 0·1% (0·1–0·3) 0·1% (0·04–0·1)
WB CD4 interleukin 17 0·1% 0·1% <0·1% (0·01–0·1) <0·1% (0·0–0·02)
Antibody responses in serum samples at week 1 (optical density values) 
MVA IgG 0·5 0·4 0·6 (0·4–1·2) 0·6 (0·5–0·9)
MVA IgA 0·2 0·3 0·4 (0·3–0·5) 0·5 (0·4–0·6)
MVA IgM 1·4 1·1 0·9 (0·7–1·2) 0·9 (0·6–1·3)
All presented data are background subtracted. pfu=plaque-forming units. PMBC=peripheral blood mononuclear cells. BAL=bronchoalveolar lavage. WB=whole blood. 
TNF=tumour necrosis factor.
Table 3: Immune responses at 1 week after vaccination in two participants who received high-dose aerosol MVA85A compared with median responses 
for participants given lower dose
Panel: Research in context
Systematic review
We searched PubMed using the terms “TB vaccine”, “aerosol”, 
and “clinical trial”, with no restrictions on our search dates or 
language. We found no reported trials of this kind, and our 
trial is the ﬁ rst report of a clinical trial in which a candidate 
tuberculosis vaccine has been delivered by aerosol to human 
participants. The only other published study used BCG, the 
only licensed vaccine against tuberculosis, delivered by 
nebuliser in a sealed room to a group of healthy human 
participants.29 In this study, two diﬀ erent nebulisation devices 
were used, and a sealed room and a small chamber were also 
compared. Rates of tuberculin skin test conversion were 
assessed in guinea pigs and healthy human participants.
Interpretation
Our trial shows that aerosol vaccination with MVA85A is 
feasible, safe, and can induce potent mycobacteria-speciﬁ c 
mucosal and systemic cellular immune responses. Further 
studies are needed to fully characterise the mucosal and 
systemic immune response to both insert and vector. This 
work is of relevance for all respiratory pathogens against 
which a mucosal immune response is desirable.
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administered BCG.29 Delivery of a tuberculosis vaccine by 
aerosol to people is not a novel approach. Nebuliser 
delivery of BCG to people induces systemic immune 
responses as measured by a tuberculin skin test.30
In this phase 1 trial, we describe the ﬁ rst aerosol 
administration of a candidate tuberculosis vaccine to 
human beings and show that the vaccine is safe and 
strongly immunogenic (panel). Further studies are 
needed to fully characterise the mucosal and systemic 
immune response to both insert and vector. This work is 
of relevance for all respiratory pathogens for which a 
mucosal immune response is desirable.
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